Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings This recently published, real-world, multi-center, retrospective study analyzed 233 ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
Topline results from the trial show that Signatera-positive patients treated with atezolizumab (Tecentriq®) had statistically significant and clinically meaningful improvements in disease-free ...
Clinical utility study in stage I-IV colorectal cancer (CRC) evaluates how adjuvant treatment decisions are impacted by using the Signatera™ MRD test AUSTIN, Texas, March 11, 2022 /PRNewswire/ -- ...
The HEROES trial explores de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using the Signatera test to guide treatment decisions. The trial aims to enroll 170 patients, focusing on ...
Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...
New findings show that Signatera status can help identify high-risk patients and inform non-operative management and surveillance strategies Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results